Literature DB >> 33021723

Behavioral, Hormonal, Inflammatory, and Metabolic Effects Associated with FGF21-Pathway Activation in an ALS Mouse Model.

J B Delaye1, D Lanznaster2, C Veyrat-Durebex3,2, A Fontaine4, G Bacle2,5, A Lefevre2, R Hergesheimer2, J C Lecron6, P Vourc'h3,2, C R Andres3,2, F Maillot2,7, P Corcia2,8, P Emond2,9, H Blasco3,2.   

Abstract

In amyotrophic lateral sclerosis (ALS), motor neuron degeneration occurs simultaneously with systemic metabolic dysfunction and neuro-inflammation. The fibroblast growth factor 21 (FGF21) plays an important role in the regulation of both phenomena and is a major hormone of energetic homeostasis. In this study, we aimed to determine the relevance of FGF21 pathway stimulation in a male mouse model of ALS (mutated SOD1-G93A mice) by using a pharmacological agonist of FGF21, R1Mab1. Mice (SOD1-WT and mutant SOD1-G93A) were treated with R1Mab1 or vehicle. Longitudinal data about clinical status (motor function, body weight) and biological parameters (including hormonal, immunological, and metabolomics profiles) were collected from the first symptoms to euthanasia at week 20. Multivariate models were performed to identify the main parameters associated with R1Mab1 treatment and to link them with clinical status, and metabolic pathways involving the discriminant metabolites were also determined. A beneficial clinical effect of R1Mab1 was revealed on slow rotarod (p = 0.032), despite a significant decrease in body weight of ALS mice (p < 0.001). We observed a decrease in serum TNF-α, MCP-1, and insulin levels (p = 0.0059, p = 0.003, and p = 0.01, respectively). At 16 weeks, metabolomics analyses revealed a clear discrimination (CV-ANOVA = 0.0086) according to the treatment and the most discriminant pathways, including sphingolipid metabolism, butanoate metabolism, pantothenate and CoA biosynthesis, and the metabolism of amino acids like tyrosine, arginine, proline, glycine, serine, alanine, aspartate, and glutamate. Mice treated with R1Mab1 had mildly higher performance on slow rotarod despite a decrease on body weight and could be linked with the anti-inflammatory effect of R1Mab1. These results indicate that FGF21 pathway is an interesting target in ALS, with a slight improvement in motor function combined with metabolic and anti-inflammatory effects.

Entities:  

Keywords:  Amyotrophic lateral sclerosis; FGF21; Metabolomics; R1Mab1; SODG93A; Therapeutic antibody

Mesh:

Substances:

Year:  2020        PMID: 33021723      PMCID: PMC8116478          DOI: 10.1007/s13311-020-00933-3

Source DB:  PubMed          Journal:  Neurotherapeutics        ISSN: 1878-7479            Impact factor:   7.620


  33 in total

1.  Peripheral nerve inflammation in ALS mice: cause or consequence.

Authors:  Osamu Kano; David R Beers; Jenny S Henkel; Stanley H Appel
Journal:  Neurology       Date:  2012-02-29       Impact factor: 9.910

2.  Analytical methodology for metabolomics study of adherent mammalian cells using NMR, GC-MS and LC-HRMS.

Authors:  Blandine Madji Hounoum; Hélène Blasco; Lydie Nadal-Desbarats; Binta Diémé; Frédéric Montigny; Christian R Andres; Patrick Emond; Sylvie Mavel
Journal:  Anal Bioanal Chem       Date:  2015-10-07       Impact factor: 4.142

Review 3.  The dual roles of immunity in ALS: injury overrides protection.

Authors:  Benjamin J Murdock; Diane E Bender; Benjamin M Segal; Eva L Feldman
Journal:  Neurobiol Dis       Date:  2015-02-26       Impact factor: 5.996

Review 4.  Energy metabolism in amyotrophic lateral sclerosis.

Authors:  Luc Dupuis; Pierre-François Pradat; Albert C Ludolph; Jean-Philippe Loeffler
Journal:  Lancet Neurol       Date:  2010-10-27       Impact factor: 44.182

5.  Computing topological parameters of biological networks.

Authors:  Yassen Assenov; Fidel Ramírez; Sven-Eric Schelhorn; Thomas Lengauer; Mario Albrecht
Journal:  Bioinformatics       Date:  2007-11-15       Impact factor: 6.937

6.  Saponins from stems and leaves of Panax ginseng prevent obesity via regulating thermogenesis, lipogenesis and lipolysis in high-fat diet-induced obese C57BL/6 mice.

Authors:  Guilin Chen; Haijun Li; Yan Zhao; Hongyan Zhu; Enbo Cai; Yugang Gao; Shuangli Liu; He Yang; Lianxue Zhang
Journal:  Food Chem Toxicol       Date:  2017-06-07       Impact factor: 6.023

7.  A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group.

Authors:  G Bensimon; L Lacomblez; V Meininger
Journal:  N Engl J Med       Date:  1994-03-03       Impact factor: 91.245

Review 8.  Prognostic factors in ALS: A critical review.

Authors:  Adriano Chiò; Giancarlo Logroscino; Orla Hardiman; Robert Swingler; Douglas Mitchell; Ettore Beghi; Bryan G Traynor
Journal:  Amyotroph Lateral Scler       Date:  2009 Oct-Dec

9.  Metabolomics Study of Urine in Autism Spectrum Disorders Using a Multiplatform Analytical Methodology.

Authors:  Binta Diémé; Sylvie Mavel; Hélène Blasco; Gabriele Tripi; Frédérique Bonnet-Brilhault; Joëlle Malvy; Cinzia Bocca; Christian R Andres; Lydie Nadal-Desbarats; Patrick Emond
Journal:  J Proteome Res       Date:  2015-11-23       Impact factor: 4.466

10.  KEGG for linking genomes to life and the environment.

Authors:  Minoru Kanehisa; Michihiro Araki; Susumu Goto; Masahiro Hattori; Mika Hirakawa; Masumi Itoh; Toshiaki Katayama; Shuichi Kawashima; Shujiro Okuda; Toshiaki Tokimatsu; Yoshihiro Yamanishi
Journal:  Nucleic Acids Res       Date:  2007-12-12       Impact factor: 16.971

View more
  1 in total

Review 1.  The Role and Therapeutic Potential of the Integrated Stress Response in Amyotrophic Lateral Sclerosis.

Authors:  Elías Marlin; Cristina Viu-Idocin; Montserrat Arrasate; Tomás Aragón
Journal:  Int J Mol Sci       Date:  2022-07-15       Impact factor: 6.208

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.